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Abstract
Objective—The etiology of Parkinson disease (PD) is complex and multifactorial, with
hereditary and environmental factors contributing. Monogenic forms have provided molecular
clues to disease mechanisms but genetic modifiers of idiopathic PD are still to be determined.
Methods—We carried out whole-genome expression profiling of isolated human substantia nigra
(SN) neurons from patients with PD vs. controls followed by association analysis of tagging
single-nucleotide polymorphisms (SNPs) in differentially regulated genes. Association was
investigated in a German PD sample and confirmed in Italian and British cohorts.
Results—We identified four differentially expressed genes located in PD candidate pathways, ie,
MTND2 (mitochondrial, p = 7.14 × 10−7), PDXK (vitamin B6/dopamine metabolism, p = 3.27 ×
10−6), SRGAP3 (axon guidance, p = 5.65 × 10−6), and TRAPPC4 (vesicle transport, p = 5.81 ×
10−6). We identified a DNA variant (rs2010795) in PDXK associated with an increased risk of PD
in the German cohort (p = 0.00032). This association was confirmed in the British (p = 0.028) and
Italian (p = 0.0025) cohorts individually and reached a combined value of p = 1.2 × 10−7 (odds
ratio [OR], 1.3; 95% confidence interval [CI], 1.18–1.44).
Interpretation—We provide an example of how microgenomic genome-wide expression studies
in combination with association analysis can aid to identify genetic modifiers in
neurodegenerative disorders. The detection of a genetic variant in PDXK, together with evidence
accumulating from clinical studies, emphasize the impact of vitamin B6 status and metabolism on
disease risk and therapy in PD.
Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by age-related
dysfunction and loss of dopaminergic neurons in the substantia nigra (SN) pars compacta
(SNc). Hereditary forms of PD have provided evidence for linkage to 13 loci and nine
causative genes, and their functional study has greatly helped to elucidate molecular disease
mechanisms.1 For idiopathic PD, both genetic and environmental factors are believed to
modulate disease risk, but the impact of genetic variants remains unclear.2 Genome-wide
association (GWA) studies offer an unbiased approach for detecting effects in common
variants, but large studies with sufficient power are still lacking. Restriction to candidate
genes increases the a priori odds for phenotypic involvement and thus the chance of
detecting significant associations. Here, we applied a functional genomic approach for the
discovery of candidate genes and key regulatory pathways. We focused directly on the
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affected tissue and specifically on dopaminergic neurons of the SNc using single cell,
whole-genome expression profiling followed by a genetic association study of differentially
regulated genes.
Materials and Methods
Tissue Samples for Expression Profiling
Frozen human brain tissue was obtained from the Newcastle Brain Tissue Resource.
Samples were available from patients with a clinical history of PD fulfilling UK PD Brain
Bank criteria and from age-matched control individuals without neurological disease. The
cases were clinically well documented and neuropathologically confirmed. Inclusion criteria
comprised the neuropathological diagnosis of Lewy body disease with typical pathological
features, including moderate to severe dopaminergic neuronal loss in the SNc and gliosis.
The local research ethics committee approved all procedures.
Sectioning, Staining, Laser Microdissection, In Vitro Transcription, and Microarray
In order to isolate high-quality RNA from frozen human brain tissues, tissue pH and RNA
integrity numbers (RIN) were measured in homogenates of frontal cortex and mid-brain
sections from 41 suitable cases and 39 controls. This provided eight cases and nine age-
matched controls of good RNA quality for laser microdissection (LMD). Postmortem data
for matched cases/controls were as follows: age at death 78.6 ± 6.5/76.8 ± 9.8 years;
postmortem delay 28.3 ± 11.9/20.5 ± 10.2 hours; pH 6.5 ± 0.1/6.61 ± 0.21; and RIN 7.7 ±
0.8/7.6 ± 1.1 (Supporting Table 1; Supporting Fig 1).All procedures were carried out under
RNAse-free conditions. Frozen 20μm midbrain sections were mounted on Leica PEN-slides
(Leica, Wetzlar, Germany), rapidly stained with toluidine blue, dehydrated in an ethanol
series, and processed on a Leica LMD microscope. A total of 100 neurons per case/control
were collected and RNA was extracted with the PicoPure® Kit (Molecular Devices,
Sunnyvale, CA) according to the manufacturer’s protocol. In two cases and two controls
sampling and experiments were repeated to enable analysis of reproducibility. In vitro
transcription (IVT) comprised one round of linear amplification with MessageAmpII
(Applied Biosystems/Ambion, Austin, TX), followed by a second round of IVT with the
Illumina® TotalPrep™ RNA Amplification Kit (Ambion). Second-round IVT yielded >3μg
cRNA with an average length of 800bp and was used for hybridization on Illumina WG6v1
expression chips (Illumina, San Diego, CA). On average, more than 12,000 transcripts were
detected (p < 0.01). For validation of microarray results, excess aRNA was reverse-
transcribed using SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen, Carlsbad,
CA) and assayed on a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster
City, CA) using TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA)
by following standard protocols. Beta-actin was used as a housekeeping gene and relative
expression of the two most significant genes was determined. Data was analyzed using the
comparative C(T) method.3
Statistical Analysis of Microarray Data
Raw data were exported from the Illumina Beadstudio software to R (http://cran.r-
project.org), log-scale transformed (log2) and normalized (nonlinear transformation
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employing the LOESS smoother).4 A total of 8,491 transcripts were detected in all samples.
Statistical analysis (t test) revealed no significant difference for age, postmortem delay,
tissue pH, and RIN number of postmortem samples, and no associated effect was seen on
gene expression. To select significant signals in the transcriptome-wide differential (t test)
screening, conservative Bonferroni thresholds were used, which corresponded to a nominal
level of 0.05.
Single-Nucleotide Polymorphism Analysis and German Cohort
Single-nucleotide polymorphism (SNP) selection was performed with the Tagger algorithm
in Haploview 4.1 (http://www.broad.mit.edu/mpg/tagger) using pairwise tagging only, an r2
threshold of 0.8, and a minor allele frequency (MAF) of 0.1. Genotype data were taken from
the CEU population in HapMap (data Rel 23a/phaseII Mar08). Selection of SNPs was
restricted to those that were covered by the Illumina Hap550 array, since genotyping data
from this platform in universal German controls was used for analysis. The genomic regions
of both genes were defined as the transcriptional unit plus 10kb upstream and downstream.
Twelve tagging SNPs for PDXK and five tagging SNPs for TRAPPC4 were selected.
German PD patients were recruited by participating institutions in Munich and Tuebingen.
Specialists in movement disorders examined the patients. Diagnosis was established
according to UK PD Brain Bank criteria. Geno-typing of 676 German PD patients were
performed on a Sequenom MassArray system with the iPlex Gold assay (Sequenom, San
Diego, CA). A total of 15 assays had call rates of >98%. With the exception of one SNP
(rs743463; Pearson p = 0.04) no deviations from Hardy-Weinberg equilibrium (HWE) were
observed. The Armitage Trend Test was performed for association using our genotype data
for the 676 PD patients and available Illumina Hap550 genotyping data from 485 KORA
and 487 POPGEN universal German controls.5,6
British Cases and Controls
For the British cohort, a group of community-based cases with PD fulfilling UK PD Brain
Bank criteria (n = 203) were compared to a group of ethnically age- and gender-matched
controls (n = 142), with no clinical evidence of PD. All were of UK Caucasian origin. Two
additional UK control groups were included to increase statistical power: The Orkney
Complex Disease Study (ORCADES) is an ongoing, family-based, cross-sectional study in
the isolated Scottish archipelago of Orkney. Data for participants aged 18 to 100 years, from
a subgroup of 10 islands, were used for this analysis. The mean age was 53 years and 53%
were female. Genetic diversity in this population is decreased compared to Mainland
Scotland, consistent with the historically high levels of endogamy. Therefore, from 719
available samples, first-, second-, and third-degree relatives were excluded, resulting in 483
samples used for this study. All participants gave informed consent and the Research Ethics
Committees in Orkney and Aberdeen approved the study. In the Study of Colon Cancer
Survivors (SOCCS), 1,012 colorectal cancer cases were recruited from throughout mainland
Scotland; 1,012 age- and gender-matched cancer-free population controls were selected at
random according to matching criteria from a population-based register (518 males, 494
females; age 51.0 ± 5.9 years, mean ± standard deviation [SD]). From these, 503 samples
were randomly selected for our study. Genotyping was conducted using Illumina
HumanHap300 and Illumina Human-Hap240S arrays according to established protocols.7
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Italian Cases and Controls
The Italian cohort comprised 356 unrelated, nonfamilial PD patients, fulfilling the criteria
for PD reported in Ghezzi et al.8 The study was in agreement with the UK PD Brain Bank
criteria. The male/female ratio was 1.72; the age range was 50 to 75 years (67 ± 6.6). The
control group included 171 unrelated, ethnically- and age-matched controls (male/female
ratio 0.4; age range 50–75 years; age 59 ± 16.3 years) with no clinical evidence of PD. All
were Italians of Caucasian origin. All of the participants gave informed consent. One
additional control group from Italy was included to increase statistical power. The Val
Borbera Project is an ongoing family-based, cross-sectional study in the isolated population
of the Val Borbera in Northwest Italy. Data for participants aged 18 to 102 years, from the
seven villages of the valley, were used for this analysis. The mean age was 55 years and
56% were female. The population presents a high level of endogamy until around 1950.
From the 1,436 samples genotyped, individuals presenting a Ks coefficient ≥ 0.05 (first-,
second-, and third-degree relatives) were excluded, resulting in 532 samples used for this
study. All participants gave informed consent and the Ethics Committees of the San Raffaele
Hospital and of the Piemonte Region approved the study.
Results
Gene expression profiles of 100 SNc neurons collected from the same brain sample, which
were carried through LMD, IVT, and array hybridization individually, displayed an
extremely high correlation (Fig 1). This degree of reproducibility strengthened confidence in
the method used. Statistical analysis of the genome-wide expression profiles using stringent
Bonferroni correction revealed four transcripts to be significantly altered between PD and
control samples: the mitochondrial encoded complex I subunit gene ND2 (mtND2),
pyridoxal (pyridoxine, vitamin B6) kinase (PDXK), SLIT-ROBO Rho guanosine
triphosphatase (GTPase) activating protein 3 (SRGAP3), and trafficking protein particle
complex 4 (TRAPPC4) (Fig 2; Table 1). Upregulation of ND2 and PDXK was confirmed by
real-time analysis (ND2: +2.5-fold; PDXK: +1.8-fold). In addition to ND2, a further 17
genes coding for subunits of the mitochondrial respiratory chain were among the top 320
differentially regulated transcripts (significantly changed applying a false discovery rate, p <
0.025).9 The Database for Annotation, Visualization, and Integrated Discovery (DAVID)
gene functional classification tool revealed a highly significant enrichment in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway “oxidative phosphorylation” (p =
5.6 × 10−9).10 Interestingly, the mtDNA-encoded genes were all found to be upregulated:
ND1 (p = 0.0002; +1.65-fold), ND2 (p = 7.14 × 10−7; +1.7-fold), ND4 (p = 0.0005; +1.27-
fold), ND5 (p = 0.0002; +1.69-fold), and COXII (p = 0.00039; +1.31-fold). In contrast, the
13 nuclear genes coding for different members of the five respiratory chain complexes were
robustly downregulated. Mitochondrial dysfunction in the pathogenesis of PD is clearly
established,11 but our findings demonstrate an inverse regulation of mtDNA and nuclear-
encoded subunits of the respiratory chain on a single-cell basis, which has been reported by
Noureddine et al.12 and Duke et al.13 in gross dissections of SN tissue.
In order to validate a causal involvement of the new candidates in the pathogenesis of PD,
we decided to follow a genetic approach. Since mtDNA variants and polymorphisms in the
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axon guidance pathway have already been shown to be involved in prior studies, our
investigation was restricted to PDXK and TRAPPC4.14,15 No association was seen for
tagging SNPs in the TRAPPC4 gene. By contrast, in PDXK, two SNPs with r2 = 0.29
reached significant p values for association with disease status: rs2010795 (p = 3.2 × 10−4;
odds ratio [OR], 1.319; 95% confidence interval [CI], 1.134–1.534) lies in intron 8 and
rs2070535 (p = 6.4 × 10−4; OR, 0.783; 95% CI, 0.681–0.901) in the 3′ untranslated region
of the PDXK gene (Fig 3). Replication genotyping of the two lead SNPs in 203 PD and
1,126 control samples from the UK cohort confirmed the association of rs2010795 with PD
(p = 0.028) giving a similar MAF in PD cases (0.34) and controls (0.29), and resulting in a
similar OR of 1.3 (95% CI, 1.03–1.61). In the Italian cohort, association for rs2010795 was
confirmed in 353 cases and 704 controls with a p value of 0.00252, again with a similar
MAF (PD = 0.35, controls = 0.29) and OR (1.35; 95% CI, 1.11–1.63). In the combined
analysis of 1,232 PD and 2,802 control individuals, the association of SNP rs2010795
reached a p value of 1.18 × 10−7 (combined OR, 1.304; 95% CI, 1.178–1.444). Details on
allele frequency are given in Table 2. The geographic distribution of PD and control
sampling sites is shown in Supporting Figure 2.
Discussion
Integrating gene expression with association analysis data is a promising approach for the
study of disease biology. This concept, termed genomic convergence, was first proposed by
Hauser et al.16 and aims to narrow down a large pool of candidate genes to a few selected
choices. With four biologically plausible candidates being differentially expressed in SNc
neurons of PD samples, we aimed to evaluate their contribution in idiopathic PD. If
differential regulation of these genes is involved in the pathogenesis of PD, their genetic
variants might affect the risk for disease.
mtDNA variants and polymorphisms in the axon guidance pathway have been investigated
in prior genetic studies. For example, the mitochondrial UKJT haplogroup was shown to be
associated with a decreased risk of PD.2,8,14 We also demonstrate that multiple mtDNA
genes are upregulated, supporting previous observations that mitochondrial abnormalities
are present in SN neurons from patients with PD.11 The axon guidance pathway was
recently implicated in the pathogenesis of PD by a systematic analysis of GWA PD
studies.15,17 Ephrin, netrin, semaphorin, and slit proteins are the main effectors of the axon
guidance pathway and are important for brain development, dopaminergic axonal
maintenance, regeneration, and target recognition. Lesnick et al.15 used the combined SNP
information, rather than individual variants, to predict PD susceptibility, survival free of PD,
and PD age at onset with extremely high power.15 Together with subsequent studies, two out
of four GWA PD studies show this significant association.18,19 With the identification of
differential regulation of SRGAP3 in dopaminergic neurons of the SNc, we provide
functional data supporting the importance of the axon guidance pathway in the development
of PD.
TRAPPC4 appears to be a good candidate as it is localized in neuronal synapses and is part
of the human transport protein particle complex I that is required for tethering endoplasmic
reticulum (ER)-derived vesicles to Golgi membranes.20,21 Evidence for impaired synaptic
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vesicle endocytosis as well as disrupted ER-to-Golgi transport in PD comes from recent
studies into the role of the PD proteins alpha-synuclein and LRRK2.22,23 Since no SNP in
TRAPPC4 was significantly associated with disease in our study based on 676 cases, the
causal involvement could not be shown. Either the differential expression pattern of
TRAPPC4 is a consequence of the PD pathology or the effect size is to small to be shown in
a study of this size.
PDXK catalyzes the conversion of vitamin B6 (pyridoxine, pyridoxal, and pyridoxamine) to
pyridoxal 5′-phosphate (PLP), which is thought to be a cofactor in multiple eukaryotic
enzyme-catalyzed reactions. Of direct relevance to PD, the second step in the biosynthesis of
dopamine by the enzyme aromatic L-amino acid decarboxylase (dopa decarboxylase
[DDC]) is dependent on PLP as a cofactor and becomes rate-limiting in patients receiving L-
DOPA therapy (L-DOPA + pyridoxal phosphate = dopamine + pyridoxal phosphate +
CO2).24 A recent clinical phase I trial showed promising results of intrastriatal induction of
DDC gene expression in PD patients.25 Upregulation of PDXK in dopaminergic neurons
may be explained by an adaptive mechanism to increased dopamine metabolism in the
remaining functional dopaminergic neurons of the SNc or to L-DOPA therapy. Treatment
strategies of PD with pyridoxine were published as early as 1954, but abandoned because of
metabolic interaction with the therapeutically more potent L-DOPA in the periphery.26
Today, this effect can be negated in the presence of a peripheral DDC inhibitor and a recent
study showed that high doses of pyridoxine therapy (at 400mg/day) might be beneficial for
the treatment of PD.24 Independent of L-DOPA therapy, a prospective, population-based
cohort study showed that dietary vitamin B6 might decrease the risk of PD, although this
effect was restricted to smokers.27
SNP analysis showed a significant influence of the marker rs2010795 on disease status in
our study. Our data is the first to indicate an effect of polymorphisms in the PDXK gene on
the risk for PD, possibly by influencing enzyme amount or activity in dopaminergic neurons
of the SNc. The effect size of this marker is small and the power of current GWA studies
would be to low for significant detection. Candidate gene selection for association studies
was based on experimental data coming from microarray gene expression analysis, thus
providing the link to a likely biological effect. We therefore introduce this promising
approach for the study of genetic risk factors in complex neurodegenerative disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1.
Correlation of individual genome-wide expression profiles. Plot shows correlation of two
genome-wide expression profiles after individual LMD and IVT of 100 neurons collected
from the same SNc. Axes show normalized expression values (log2) with a range of
expression levels nearing three orders of magnitude. The resulting Pearson product-moment
correlation coefficient is r = 0.986.
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Fig 2.
Differentially regulated genes identified by whole-genome expression analysis. Four
significant genes after stringent Bonferroni correction: Box plots are showing normalized
expression (log2) of significant genes in PD samples (light gray) compared to controls
(black). Insets show fold change of gene expression as measured by real-time PCR.
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Fig 3.
Gene structure of PDXK and position of SNPs. The gene structure of PDXK and position of
SNP rs2010795 in intron 8 and of rs2070535 in the 3′ untranslated region. OR = odds ratio;
CI = confidence interval.
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Table 1
Description of Significant Genes Identified by Whole Genome Expression
Symbol Definition Fold change p-Value KEGG pathway/reactome event Biological process
MTND2
Homo sapiens
NADH
dehydrogenase,
subunit 2 (complex
I)
up 1.70 7.14 × 10−7 Oxidative phosphorylation/electrontransport chain
ATP synthesis coupled electron
transport
PDXK
Homo sapiens
pyridoxal
(pyridoxine, vitamin
B6) kinase
up 1.32 3.27 × 10−6 Vitamin B6/dopamine metabolism Pyridoxine biosynthetic process
SRGPA3
Homo sapiens SLIT-
ROBO Rho GTPase
activating protein 3
up 1.23 5.65 × 10−6 Axon guidance/signaling by RhoGTPases Signal transduction
TRAPPC4
Homo sapiens
trafficking protein
particle complex 4
down 1.69 5.8 × 10−6 Vesicle tethering and fusion ER to Golgi vesiclemediatedtransport
KEGG = Kyoto Encyclopedia of Genes and Genomes; NADH = reduced nicotinamide adenine dinucleotide; ATP = adenosine triphosphate; SLIT-
ROBO = SLIT-roundabout; GTPase = guanosine triphosphatase; ER = endoplasmic reticulum.
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